68% returns in just 3 months: Pharma stock locked in the 5% upper circuit, FIIs increased stake in last quarter; Do you own it?

On Wednesday, shares of  Venus Remedies locked in the 5 per cent upper circuit at Rs 526.50 per share from its previous closing of Rs 501.45 per share. The shares of the company saw a volume of 1.38 lakh till 10:57 am IST. The stock also made a new 52-week high of Rs 526.50 per share, and its 52-week low is Rs 270.25 per share. In just 6 months, the stock is up by 68.40 per cent.

Incorporated in 1989, Venus Remedies Ltd is a research-based pharmaceutical company and an injectable manufacturer.  VSR is one of the largest manufacturers of meropenem antibiotics and an emerging player in the AMR drug market in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti-infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, and skin & wound care. The company has 1040+ marketing authorisations globally, 135+ patents and 180+ products basket, which includes formulations such as injectables, tablets, and topical preparations.

The Board of Directors has scheduled the 36th Annual General Meeting (AGM) for August 22, 2025, at 11:30 AM IST via video conferencing. The Register of Members and Share Transfer Books will remain closed from August 16 to August 22, 2025, for AGM purposes.

In the latest quarter of March 2025, FIIs have increased their stake from 1.11 per cent to 11.34 per cent. The company has a market cap of over Rs 700 crore and has delivered good profit growth of 70 per cent CAGR over the last 5 years. In FY25, the company did net sales of Rs 648 crore and net profit of Rs 45 crore. The stock has given almost multibagger returns of over 94.08 per cent from its 52-week low of Rs 270.25 per share and a whopping 655 per cent in 5 years.

Disclaimer: The article is for informational purposes only and not investment advice.